Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Receivables - Net: 2015-2024

Historic Receivables - Net for Spyre Therapeutics (SYRE) over the last 1 years, with Dec 2024 value amounting to $5.9 million.

  • Spyre Therapeutics' Receivables - Net was N/A to $5.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.9 million, marking a year-over-year change of. This contributed to the annual value of $5.9 million for FY2024, which is N/A change from last year.
  • Per Spyre Therapeutics' latest filing, its Receivables - Net stood at $5.9 million for Q4 2024, which was down 0.00% from $5.9 million recorded in Q3 2024.
  • Over the past 5 years, Spyre Therapeutics' Receivables - Net peaked at $21.5 million during Q1 2021, and registered a low of $5.9 million during Q2 2024.
  • In the last 1 years, Spyre Therapeutics' Receivables - Net had a median value of $5.9 million in 2024 and averaged $5.9 million.